

# 2008 MILESTONES

## LOOKING FORWARD

Our drug development programs made important progress in the last year as we initiated four clinical trials and disclosed positive Phase 1 and Phase 2 results for four compounds. In 2008, we will further advance our products through the pipeline, continuing to prioritize our Phase 3 program in BPH with cetrorelix and our Phase 2 program with AEZS-108 in endometrial and ovarian cancer.

## 2008

### Q1

- › Initiate European efficacy trial for cetrorelix Phase 3 program in BPH
- › Initiate safety trial for cetrorelix Phase 3 program in BPH

### Q2

- › Full recruitment for U.S. efficacy trial for cetrorelix Phase 3 program in BPH
- › Initiate QTc study for cetrorelix in BPH
- › Preclinical results at AACR for Erk/PI3K

### Q3

- › Full recruitment for EU efficacy trial for cetrorelix Phase 3 program in BPH
- › Full recruitment for safety trial for cetrorelix Phase 3 program in BPH

### Q4

- › QTc results for cetrorelix in BPH
- › Initiate proof-of-concept trial for ghrelin antagonist
- › IMPD\* filing for AEZS-120
- › Top-line results for perifosine + radiotherapy Phase 2 program
- › Initiate Phase 2 trial for AEZS-112

\* Investigational Medicinal Product Dossier

## 2009

- › Phase 2 trial results for AEZS-108
- › Results from North American Phase 3 program for cetrorelix in BPH
- › Results from EU Phase 3 program for cetrorelix in BPH
- › Results from safety study from Phase 3 program for cetrorelix in BPH